As of 2026-03-26, the EV/EBITDA ratio of Altimmune Inc (ALT) is -3.85. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Altimmune's latest enterprise value is 363.99 mil USD. Altimmune's TTM EBITDA according to its financial statements is -94.57 mil USD. Dividing these 2 quantities gives us the above Altimmune EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 16.0x | 14.8x |
| Forward P/E multiples | 19.2x - 25.5x | 21.3x |
| Fair Price | (16.04) - (13.33) | (15.04) |
| Upside | -584.6% - -502.6% | -554.5% |
| Date | EV/EBITDA |
| 2026-03-24 | -3.77 |
| 2026-03-23 | -4.00 |
| 2026-03-20 | -3.88 |
| 2026-03-19 | -3.98 |
| 2026-03-18 | -3.98 |
| 2026-03-17 | -4.11 |
| 2026-03-16 | -4.22 |
| 2026-03-13 | -4.08 |
| 2026-03-12 | -4.20 |
| 2026-03-11 | -4.43 |
| 2026-03-10 | -4.51 |
| 2026-03-09 | -4.53 |
| 2026-03-06 | -4.12 |
| 2026-03-05 | -4.08 |
| 2026-03-04 | -4.99 |
| 2026-03-03 | -4.86 |
| 2026-03-02 | -4.86 |
| 2026-02-27 | -5.04 |
| 2026-02-26 | -5.22 |
| 2026-02-25 | -5.34 |
| 2026-02-24 | -5.35 |
| 2026-02-23 | -5.29 |
| 2026-02-20 | -5.13 |
| 2026-02-19 | -5.26 |
| 2026-02-18 | -5.22 |
| 2026-02-17 | -5.27 |
| 2026-02-13 | -5.30 |
| 2026-02-12 | -5.35 |
| 2026-02-11 | -5.42 |
| 2026-02-10 | -5.45 |
| 2026-02-09 | -5.50 |
| 2026-02-06 | -5.71 |
| 2026-02-05 | -5.77 |
| 2026-02-04 | -6.02 |
| 2026-02-03 | -6.43 |
| 2026-02-02 | -6.52 |
| 2026-01-30 | -6.58 |
| 2026-01-29 | -5.98 |
| 2026-01-28 | -6.01 |
| 2026-01-27 | -7.27 |
| 2026-01-26 | -6.65 |
| 2026-01-23 | -6.46 |
| 2026-01-22 | -6.32 |
| 2026-01-21 | -5.41 |
| 2026-01-20 | -4.95 |
| 2026-01-16 | -4.96 |
| 2026-01-15 | -4.96 |
| 2026-01-14 | -4.89 |
| 2026-01-13 | -4.68 |
| 2026-01-12 | -4.73 |